Articles
This section provides a brief overview of new cancer drugs and new indications
approved by the FDA between February 9, 2023, and April 3, 2023. Read More ›
The FDA has issued a final rule intended to ensure patients are better informed about their breast tissue density when undergoing mammography. Read More ›
By William King
Molecular/genetic characterization has taken on greater importance in the classification of adult gliomas and in diagnostic and treatment decision-making. “These tumors are now grouped and predicated more on molecular features rather than histopathologic criteria,” said L. Burt Nabors, MD, in a presentation during the 2023 National Comprehensive Cancer Network Annual Conference. Read More ›
By William King
In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, and identified key factors for selecting frontline and subsequent therapies, including immunoglobulin heavy chain variable gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations. Read More ›
By William King
Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the 2023 National Comprehensive Cancer Network Annual Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib, sunitinib, and other tyrosine kinase inhibitors. Read More ›
The results of a recent survey commissioned by AccessOne, which focused on healthcare affordability and the impact of rising costs of living, revealed that the majority (71%) of consumers feel that inflation is having a significant effect on their healthcare purchasing decisions or their ability to pay medical bills. Read More ›
By William King
During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care. Read More ›
Updated results from a large clinical trial confirm that, for some patients with bladder cancer that can be removed with surgery, receiving immunotherapy immediately afterwards is an effective treatment. Read More ›
"Immunotherapy After Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer” was originally published by the National Cancer Institute.
By Karen Blum
Early last year, Jerome Wohleb, PharmD, MBA, FASHP, Pharmacy Services Director, Bryan Medical Center, Lincoln, NE, faced a dilemma. A Nebraska Pharmacy Workforce Survey revealed a high level of burnout among pharmacists in the aftermath of the COVID-19 pandemic. Read More ›
Older Black and Hispanic patients with advanced cancer are less likely than White patients to receive opioid medications for pain relief in the last weeks of life, according to the results of a recent study published in the Journal of Clinical Oncology. Read More ›